Daily Endocrinology Research Analysis
A phase 3 randomized trial showed that the oral small-molecule GLP-1 receptor agonist orforglipron produced substantial, dose-dependent weight loss and cardiometabolic improvements in adults with obesity. Complementing this, a Nature Metabolism study uncovered how the exercise-linked metabolite Lac-Phe suppresses feeding by inhibiting hypothalamic AgRP neurons, while an optics advance demonstrated label-free, noninvasive single-cell HbA1c measurement and retrospective glycemic history reconstruc
Summary
A phase 3 randomized trial showed that the oral small-molecule GLP-1 receptor agonist orforglipron produced substantial, dose-dependent weight loss and cardiometabolic improvements in adults with obesity. Complementing this, a Nature Metabolism study uncovered how the exercise-linked metabolite Lac-Phe suppresses feeding by inhibiting hypothalamic AgRP neurons, while an optics advance demonstrated label-free, noninvasive single-cell HbA1c measurement and retrospective glycemic history reconstruction using color-resolved THG microscopy.
Research Themes
- Obesity therapeutics and GLP-1 receptor pharmacology
- Neuroendocrine mechanisms of appetite regulation
- Noninvasive, label-free diabetes diagnostics and glycemic history
Selected Articles
1. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
In a 72-week, double-blind phase 3 RCT of 3127 adults with obesity, orforglipron produced dose-dependent weight loss up to −11.2% (36 mg) versus −2.1% with placebo, with significant improvements in waist circumference, systolic BP, triglycerides, and non-HDL cholesterol. Gastrointestinal events were the most common adverse events, generally mild to moderate, with discontinuations in 5.3–10.3% across orforglipron doses.
Impact: This is the first large phase 3 trial demonstrating robust efficacy of a nonpeptide, once-daily oral GLP-1 receptor agonist for obesity, potentially expanding access and adherence compared to injectables.
Clinical Implications: Oral GLP-1RA therapy may become a practical first-line or adjunct option for obesity management, particularly for patients preferring pills or with injection barriers; monitoring for GI tolerability and tailoring dose is important.
Key Findings
- Mean weight change at 72 weeks: −7.5% (6 mg), −8.4% (12 mg), −11.2% (36 mg) vs −2.1% with placebo (P<0.001).
- At 36 mg, 54.6%, 36.0%, and 18.4% achieved ≥10%, ≥15%, and ≥20% weight loss, respectively, vs 12.9%, 5.9%, and 2.8% with placebo.
- Waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol improved significantly versus placebo.
Methodological Strengths
- Multinational, randomized, double-blind, placebo-controlled phase 3 design with large sample size (n=3127).
- Dose-ranging evaluation with prespecified ITT estimand over a 72-week follow-up.
Limitations
- Placebo comparator without active GLP-1RA head-to-head comparison.
- Population excluded diabetes; generalizability to people with T2D requires dedicated trials.
Future Directions: Head-to-head trials versus established injectable incretin therapies, evaluation in T2D and comorbid populations, and long-term cardiovascular outcomes and safety studies.
BACKGROUND: Orforglipron, a small-molecule, nonpeptide oral glucagon-like peptide-1 (GLP-1) receptor agonist, is being investigated as a treatment for obesity. METHODS: In this phase 3, multinational, randomized, double-blind trial, we examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in a 3:3:3:4 ratio) as an adjunct to healthy diet and physical activity for 72 weeks. All the patients had obesity without diabetes mellitus. The primary end point was the percent change in body weight from baseline to week 72, as assessed according to the treatment-regimen estimand in the intention-to-treat population. RESULTS: A total of 3127 patients underwent randomization. The mean change in body weight from baseline to week 72 was -7.5% (95% confidence interval [CI], -8.2 to -6.8) with 6 mg of orforglipron, -8.4% (95% CI, -9.1 to -7.7) with 12 mg of orforglipron, and -11.2% (95% CI, -12.0 to -10.4) with 36 mg of orforglipron, as compared with -2.1% (95% CI, -2.8 to -1.4) with placebo (P<0.001 for all comparisons with placebo). Among the patients in the orforglipron 36-mg group, 54.6% had a reduction of 10% or more, 36.0% had a reduction of 15% or more, and 18.4% had a reduction of 20% or more, as compared with 12.9%, 5.9%, and 2.8% of the patients, respectively, in the placebo group. Waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels significantly improved with orforglipron treatment as compared with placebo. Adverse events resulted in treatment discontinuation in 5.3 to 10.3% of the patients in the orforglipron groups and in 2.7% of those in the placebo group. The most common adverse events with orforglipron were gastrointestinal effects, which were mostly mild to moderate. CONCLUSIONS: In adults with obesity, 72-week treatment with orforglipron led to significantly greater reductions in body weight than placebo; the adverse-event profile was consistent with that of other GLP-1 receptor agonists. (Funded by Eli Lilly; ATTAIN-1 ClinicalTrials.gov number, NCT05869903.).
2. Lac-Phe induces hypophagia by inhibiting AgRP neurons in mice.
In mice, the exercise-linked metabolite Lac-Phe suppresses feeding by directly inhibiting hypothalamic AgRP neurons via KATP channel activation, which indirectly activates anorexigenic PVH neurons. Both AgRP neuron inhibition and PVH activation are necessary for Lac-Phe–induced hypophagia, defining a neural mechanism for its anti-obesity effects.
Impact: This study uncovers a precise neural mechanism linking a circulating exercise metabolite to appetite suppression, identifying KATP-mediated AgRP neuron inhibition as a potential anti-obesity therapeutic target.
Clinical Implications: While preclinical, the Lac-Phe–AgRP–KATP axis suggests new strategies to pharmacologically suppress appetite and enhance weight loss by targeting hypothalamic circuitry.
Key Findings
- Lac-Phe directly inhibits hypothalamic AgRP neurons and indirectly activates anorexigenic PVH neurons.
- Both AgRP neuron inhibition and PVH activation are required to mediate Lac-Phe–induced hypophagia.
- Inhibition of AgRP neurons by Lac-Phe occurs via activation of ATP-sensitive potassium (KATP) channels.
Methodological Strengths
- Rigorous mechanistic dissection using neuronal recordings and circuit-level manipulations.
- Convergent evidence linking cellular electrophysiology to behavioral hypophagia.
Limitations
- Findings are in mice; translational applicability to humans remains to be established.
- Long-term metabolic outcomes and potential compensatory mechanisms were not assessed.
Future Directions: Define the receptor and upstream sensors for Lac-Phe in AgRP neurons, assess safety and efficacy of KATP targeting in vivo, and explore biomarkers of Lac-Phe signaling in humans.
N-Lactoyl-phenylalanine (Lac-Phe) is a lactate-derived circulating metabolite that reduces feeding and obesity, but the molecular mechanisms that underlie the metabolic benefits of Lac-Phe remain unknown. Here we show that Lac-Phe directly inhibits hypothalamic neurons that express Agouti-related protein (AgRP), resulting in an indirect activation of anorexigenic neurons in the paraventricular nucleus of the hypothalamus (PVH). Both AgRP inhibition and PVH activation are required to mediate Lac-Phe-induced hypophagia. Lac-Phe-mediated inhibition of AgRP neurons occurs through activation of the ATP-sensitive potassium (K
3. Color-resolved third harmonic generation microscopy for single-RBC HbA1c measurement and glycemic history assessment.
cTHGM is a label-free, noninvasive optical method that discriminates HbA1c from hemoglobin via subtle spectral shifts and quantifies single-RBC HbA1c in vivo and ex vivo, enabling reconstruction of multi-month glycemic histories. This platform offers high spatial and spectral resolution with minimal phototoxicity, suggesting utility for diabetes monitoring and precision care.
Impact: Introduces a fundamentally new, label-free optical modality to measure HbA1c at single-cell resolution and infer historical glycemic variability, potentially transforming diabetes diagnostics and risk stratification.
Clinical Implications: If validated clinically, cTHGM could enable noninvasive HbA1c assessment without phlebotomy, quantify intra-individual heterogeneity in glycation, and provide retrospective glycemic variability insights to guide therapy.
Key Findings
- cTHGM detects ~2-nm Soret band shifts to precisely distinguish HbA1c from hemoglobin with negligible phototoxicity.
- Single-RBC HbA1c fractions can be measured in vivo and ex vivo, revealing cellular-level HbA1c distributions.
- Decoding single-RBC HbA1c distributions enables reconstruction of glycemic trajectories over months.
Methodological Strengths
- Label-free, noninvasive optical imaging with high spatial and spectral resolution using a single broadband femtosecond laser.
- Demonstration of both in vivo and ex vivo single-cell HbA1c quantification and trajectory reconstruction.
Limitations
- Clinical validation against standard HbA1c assays in diverse cohorts is not yet reported.
- Specialized instrumentation may limit immediate clinical adoption; workflow integration and cost remain to be assessed.
Future Directions: Prospective clinical studies benchmarking cTHGM against laboratory HbA1c and CGM metrics, standardization of instrumentation, and exploration of applications in hemoglobinopathies and personalized glycemic targets.
The spectral absorption of biomolecules holds immense potential for revealing molecular identity, biological functions, and clinical diagnostics. Here, we present color-resolved third harmonic generation microscopy (cTHGM), a noninvasive method for molecular imaging based on absorption-enhanced THG response. Leveraging one single broadband femtosecond laser beam, cTHGM captures subtle absorption variations, including ~2-nanometer shifts in the Soret band, enabling precise distinction of glycated hemoglobin (HbA1c) from hemoglobin with negligible phototoxicity. We demonstrate that cTHGM measures HbA1c fractions in single red blood cells (RBCs) in vivo and ex vivo, providing noninvasive HbA1c measurement and insights into HbA1c distribution at the cellular level. In addition, cTHGM reconstructs historical glycemic trajectories by decoding single-RBC HbA1c distributions, offering a retrospective view of glycemic variability over months. This innovative method combines label-free imaging, high spatial and spectral resolution, and noninvasive manners, making it a promising tool for diabetes management, glycemic variability monitoring, and broader applications in precision medicine.